Cargando…
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies
Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapies. Human adenovirus type 5 (HAdV-C5/Ad5) is a common vector for its ease of manipulation, high production titers and capacity to transduce multiple cell types. However, effective clinical applications...
Autores principales: | Uusi-Kerttula, Hanni, Davies, James, Coughlan, Lynda, Hulin-Curtis, Sarah, Jones, Rachel, Hanna, Louise, Chester, John D., Parker, Alan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053699/ https://www.ncbi.nlm.nih.gov/pubmed/27056886 http://dx.doi.org/10.18632/oncotarget.8545 |
Ejemplares similares
-
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
por: Uusi-Kerttula, Hanni, et al.
Publicado: (2015) -
Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy
por: Hulin-Curtis, S L, et al.
Publicado: (2016) -
Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions
por: Baker, Alexander T., et al.
Publicado: (2019) -
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10
por: Bates, Emily A., et al.
Publicado: (2022) -
Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5(NULL)-A20
por: Davies, James A., et al.
Publicado: (2021)